[HTML][HTML] A double-blind randomised placebo-controlled trial of percutaneous coronary intervention for the relief of stable angina without antianginal medications …

AN Nowbar, C Rajkumar, M Foley… - …, 2022 - ncbi.nlm.nih.gov
Percutaneous coronary intervention (PCI) is frequently performed for stable angina.
However, the first blinded trial, ORBITA, did not show a placebo-controlled increment in …

[HTML][HTML] A double-blind randomised placebo-controlled trial of percutaneous coronary intervention for the relief of stable angina without antianginal medications …

AN Nowbar, C Rajkumar, M Foley, F Ahmed-Jushuf… - eurointervention.pcronline.com
Percutaneous coronary intervention (PCI) is frequently performed for stable angina.
However, the first blinded trial, ORBITA, did not show a placebo-controlled increment in …

A double-blind randomised placebo-controlled trial of percutaneous coronary intervention for the relief of stable angina without antianginal medications: design and …

A Nowbar, C Rajkumar, M Foley, F Ahmed-Jushuf… - 2023 - aru.figshare.com
Percutaneous coronary intervention (PCI) is frequently performed for stable angina.
However, the first blinded trial, ORBITA, did not show a placebo-controlled increment in …

A double-blind randomised placebo-controlled trial of percutaneous coronary intervention for the relief of stable angina without antianginal medications: design and …

AN Nowbar, C Rajkumar, M Foley, F Ahmed-Jushuf… - 2022 - pubmed.ncbi.nlm.nih.gov
Percutaneous coronary intervention (PCI) is frequently performed for stable angina.
However, the first blinded trial, ORBITA, did not show a placebo-controlled increment in …

A double-blind randomised placebo-controlled trial of percutaneous coronary intervention for the relief of stable angina without antianginal medications: design and …

AN Nowbar, C Rajkumar, M Foley… - … : Journal of Europcr in …, 2022 - europepmc.org
Percutaneous coronary intervention (PCI) is frequently performed for stable angina.
However, the first blinded trial, ORBITA, did not show a placebo-controlled increment in …